Nasser Ghaly Yousif1*
Coronavirus Disease (COVID-19), that begun from Wuhan, China and spread rapidly and to worldwide. Since, cancer patients are more susceptible to different types of infection with have higher risk of severe symptoms of COVID-19 than patients without cancer.
The objective of this study is determine mortality rate in cancer patients with COVID-19 through used systematic reviews and Meta-Analyses by searched COVID-19, cancer patients, mortality rate patients with cancer, mortality rate patients with COVID-19. In order to collect the data, valid databases (i.e., MEDLINE, ISI Web of Science, PubMed, EMBASE, Scopus, Google Scholar, and Science Direct) were systematically searched. Five hundred and forty-five (545) studies were identified on valid databases (electronic literature search) were screened by title, abstract and full-text articles were identified for eligibility. Seven study data of patients with severe COVID-19 reported higher mortality among patients with hematologic versus those with non-hematologic cancers (79.9% v 55.6%), and no difference in mortality among cancer + COVID-19 patients with comorbidity compared with those without any comorbidity (33.1% v 33.6%).
In conclusion; patients with cancer and COVID-19 had a significantly higher risk of mortality outcomes then patients with COVID-19 without cancer. Doctors and other medical staff must be tolerated take care with cancer patients in the COVID-19 visitors.
Keywords: Cancer, COVID-19, Mortality rate, Systematic reviews
Copyright © 2021 by The American Society for BioMedicine and BM-Publisher, Inc.
- Mohamadian M, Chiti H, Shoghli A, Biglari S, Parsamanesh N, Esmaeilzadeh A. COVID-19: Virology, biology and novel laboratory diagnosis. J Gene Med. 2021; 23(2): e3303.
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72? 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239-1242.
- Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med. 2021; 18(1): 298-307.
- Oh WK. COVID-19 infection in cancer patients: early observations and unanswered questions. Ann Oncol. 2020; 31(7): 838-839.
- Contini C, Di Nuzzo M, Barp N. The novel zoonotic COVID-19 pandemic: An expected global health concern. J Infect Dev Ctries. 2020;14(3): 254-264. https://doi.org/10.3855/jidc.12671
- Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020; 55(5): 2000547. https://doi.org/10.1183/13993003.00547-2020
- Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020; 13: 667-73.
- Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020; 21: e180.
- Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020; 92: 577-83.
- Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020; 17: 519-27. https://doi.org/10.20892/j.issn.2095-3941.2020.0289
- Addeo A, Friedlaender A. Cancer and COVID-19: unmasking their ties. Cancer Treat Rev. 2020; 88: 102041.
- Katopodis P, Anikin V, Randeva HS, et al. Pancancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARSCoV2 infection leading to COVID-19. Int J Oncol. 2020; 57: 533-9.
- Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020; 92: 2067-73.
- Ganatra S, Hammond SP, Nohria A. The novel coronavirus disease (COVID-19) threat for patients with cardiovascular disease and cancer. JACC Cardio Oncol. 2020; 2: 350- 355. https://doi.org/10.1016/j.jaccao.2020.03.001
- Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 - Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 545-50.
- Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of COVID-19 in New York city. N Engl J Med. 2020; 382: 2372-4.
- Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol. 2020; 21: 904-913.
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603-5.
- Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol 2020; 6: 557-9.
- Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31: 894-901.
- Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020; 21: 904-913.
- Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020; 10: 935-941.
- Lee LYW, Cazier JB, Starkey T, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395: 1919-1926.
- Mauri D, Kamposioras K, Tolia M, Alongi F, Tzachanis D. International Oncology Panel and European Cancer Patient Coalition Collaborators. Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic. Lancet Oncol. 2020; 21: 759-760.
- Richardson S, Hirsch JS, Narasimhan M, et al; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. AMA. 2020; 323(20): 2052-2059.
- Yousif NG, Najah R, Yousif G, et al. Hematological changes among Corona virus-19 patients: a longitudinal study. Sys rev pharma. 2020; 11(5): 862-866.
- Lee LY, Cazier JB, Angelis V, et al. UK Coronavirus Monitoring Project Team. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241): 1919-1926.
- Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020; 6: 1108-1110.
- Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31(7): 894-901.
- Desai A, Khaki AR, Kuderer NM. Use of real-world electronic health records to estimate risk, risk factors, and disparities for COVID-19 in patients with cancer. JAMA Oncol. 2021;7(2): 227-229.
- Kalinsky K, Accordino MK, Hosi K, et al. Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City. Breast Cancer Res Treat. 2020; 182(1): 239-242.
- Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3): 335-337.
- Gupta K, Gandhi S, Mebane A, et al. Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward. Cancer Treat Res Commun. 2021; 26: 100285.
READ THE FULL ARTICLE
For any technique error please contact us
American Journal of BioMedicine Volume 9, Issue 3, pages 156-163
Received March 19, 2021; revised May 30, 2021; accepted May 19, 2021; published May 30, 2021
How to cite this article
Yousif NG. Mortality rate in cancer patients with COVID-19: meta-analysis data. American Journal of BioMedicine 2021;9(3):156-163.